Makaram Navnit, Russell Clark D, Roberts Simon Benedict, Stevens Jarrad, Macpherson Gavin
Department of Orthopaedics and Trauma, Royal Infirmary of Edinburgh, Edinburgh, UK.
Department of Infectious Diseases and Medical Microbiology, University of Edinburgh MRC Centre for Inflammation Research, Edinburgh, UK.
BMJ Case Rep. 2018 Dec 14;11(1):e226912. doi: 10.1136/bcr-2018-226912.
We report a diagnosis of exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction (DDI) between intrabursal triamcinolone and the pharmacokinetic booster cobicistat. A 53-year-old woman living with HIV, managed with dolutegravir and cobicistat-boosted darunavir, presented to the orthopaedic clinic with worsening hip pain. She was diagnosed with greater trochanteric pain syndrome (GTPS) of the hip and was treated with intrabursal injection of bupivacaine and triamcinolone. Seven days following this injection, she presented with Cushingoid features, an undetectable cortisol and was diagnosed with exogenous steroid-induced hypoadrenalism. Cobicistat is a cytochrome P450 3A inhibitor and in this case inhibited clearance of intrabursal triamcinolone, leading to exogenous glucocorticoid excess and adrenal suppression. This is the first report to describe this predictable DDI with cobicistat following intrabursal glucocorticoid injection. This case highlights the complexities in managing non-HIV-related chronic morbidities in people living with HIV.
我们报告了一例由滑囊内注射曲安奈德与药代动力学增强剂考比司他之间的药物相互作用(DDI)导致的HIV感染者外源性类固醇诱导的肾上腺功能减退症。一名53岁的HIV感染女性,接受度鲁特韦和考比司他增强的达芦那韦治疗,因髋部疼痛加重就诊于骨科诊所。她被诊断为髋部大转子疼痛综合征(GTPS),并接受了滑囊内注射布比卡因和曲安奈德治疗。注射后7天,她出现库欣样特征,皮质醇检测不到,被诊断为外源性类固醇诱导的肾上腺功能减退症。考比司他是一种细胞色素P450 3A抑制剂,在本病例中抑制了滑囊内曲安奈德的清除,导致外源性糖皮质激素过量和肾上腺抑制。这是第一份描述滑囊内注射糖皮质激素后与考比司他发生这种可预测的DDI的报告。该病例凸显了HIV感染者非HIV相关慢性疾病管理的复杂性。